arXiv:2607. 06919v1 Announce Type: cross Abstract: Artificial intelligence (AI) analysis of micro-ultrasound ($\mu$US) has shown promise for prostate cancer (PCa) detection.
Machine-generated by The Flow from the publisher's headline and feed description — not written or checked by a human. The full article lives at arXiv Machine Learning.
The paper introduces ANT, a test‑time adaptation framework that improves prostate cancer detection in micro‑ultrasound by performing a segmentation‑guided adaptation. ANT aligns a pretrained detection encoder to the target domain’s prostate anatomy using pseudo‑masks from a frozen segmentation network, thereby correcting domain‑specific feature drift while preserving cancer‑discriminative features. In a leave‑one‑center‑out evaluation, ANT raises mean AUC by 2.9% at the biopsy‑core level and 3.6% at the patient level compared to no adaptation, outperforming existing TTA baselines.
The paper introduces a Mixture of Multicenter Experts (MoME) framework that leverages diverse clinical strategies to reduce bias in medical AI without sharing data across institutions. MoME integrates specialized expertise from multiple centers, improving generalizability and adaptability of a multimodal target volume delineation model for prostate cancer radiotherapy. The model, trained with few-shot imaging and clinical notes, outperformed baselines, especially in high inter‑center variability or limited data scenarios, and allows local customization without cross‑institutional data exchange.
arXiv:2510. 17529v3 Announce Type: replace-cross Abstract: Active Surveillance (AS) is a treatment option for managing low and intermediate-risk prostate cancer (PCa), aiming to avoid overtreatment while monitoring disease progression through serial MRI and clinical follow-up.
Active surveillance (AS) is the preferred strategy for favorable-risk prostate cancer, yet current protocols rely on scheduled repeat biopsies, most of which reveal no progression and are unnecessary. Existing risk-stratification tools operate on single time-point imaging or depend on explicit lesion segmentation, limiting their ability to capture longitudinal change and excluding patients without an MRI-visible lesion.
arXiv:2606. 30951v1 Announce Type: cross Abstract: Micro-ultrasound ($\mu$US) is a new, emerging, and promising imaging modality for prostate cancer (PCa) detection, but accurate identification of suspicious tissue remains highly dependent on clinical experience, leading to substantial inter-observer variability.
arXiv:2606. 19174v1 Announce Type: cross Abstract: Clinician-centered evaluation is critical for validating medical AI systems, especially in ultrasound imaging where quantitative metrics do not always capture clinical usability.